𝔖 Bobbio Scriptorium
✦   LIBER   ✦

HER-2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine

✍ Scribed by Serenella M. Pupa; Elda Tagliabue; Sylvie Ménard; Andrea Anichini

Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
345 KB
Volume
205
Category
Article
ISSN
0021-9541

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The oncoprotein encoded by the HER‐2 oncogene is a member of the HER family of receptor tyrosine kinases and is actually the first successfully exploited target molecule in new biomolecular therapies of solid tumors. The association of HER‐2 overexpression with human tumors, its extracellular accessibility, as well as its involvement in tumor aggressiveness are all factors that make this receptor an appropriate target for tumor‐specific therapy. In addition, HER‐2 overexpression fosters its immunogenicity, as shown by the frequency of B and T cell‐mediated responses against this oncoprotein in cancer patients, and it is being investigated as a promising molecule for either passive and active immunotherapy strategies. This review summarizes a number of immune intervention approaches that target HER‐2 in breast cancer. © 2005 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Prognostic significance of HER-2 status
Prognostic significance of HER-2 status in women with inflammatory breast cancer
✍ Shaheenah Dawood; Kristine Broglio; Yun Gong; Wei-Tse Yang; Massimo Cristofanill 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 2 views

## Abstract ## BACKGROUND Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer with poorly understood prognostic variables. The purpose of this study was to define the prognostic impact of HER‐2 status on survival outcomes of patients with IBC. ## METHODS In all, 179 pati

Targeting endothelin A receptor enhances
Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells
✍ Jeanett Fischgräbe; Martin Götte; Katharina Michels; Ludwig Kiesel; Pia Wülfing 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 600 KB

Human epidermal growth factor receptor 2 (HER2) is frequently overexpressed in human breast cancers. It is known to drive tumor growth and progression and represents a prominent target in breast cancer therapy. The endothelin (ET) system, in particular ET-1 and its receptor ET A R, is of major relev

Prognostic value of the quantitative mea
Prognostic value of the quantitative measurement of the oncoprotein p185Her-2/neu in a group of patients with breast cancer and positive node involvement
✍ Uriel Bohn; José Aguiar; Cristina Bilbao; Adolfo Murias; Victor Vega; Ricardo Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 109 KB

## Abstract Our study attempts to determine the prognostic value of the quantitative measurement of the oncoprotein p185^Her‐2/neu^ in a group of patients with breast cancer and positive node involvement. In a series of 217 patients with breast cancer and positive nodes in whom the oncoprotein p185

HER-2/neu status and tumor morphology of
HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry
✍ Louise A. Quenneville; Kelly-Anne Phillips; Hilmi Ozcelik; Robert K. Parkes; Jul 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 2 views

## Abstract ## BACKGROUND The prevalence of BRCA1 germline mutations is greater in the Ashkenazi Jewish population than in the general North American population. The Ontario Familial Breast Cancer Registry collects clinical and family history data in familial breast carcinoma cases, and unselected